DE69428595D1 - Herstellung von omeprazol und lansoprazol und dabei verwendete zwischenprodukte - Google Patents

Herstellung von omeprazol und lansoprazol und dabei verwendete zwischenprodukte

Info

Publication number
DE69428595D1
DE69428595D1 DE69428595T DE69428595T DE69428595D1 DE 69428595 D1 DE69428595 D1 DE 69428595D1 DE 69428595 T DE69428595 T DE 69428595T DE 69428595 T DE69428595 T DE 69428595T DE 69428595 D1 DE69428595 D1 DE 69428595D1
Authority
DE
Germany
Prior art keywords
lansoprazole
omeprazole
production
intermediate products
products used
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69428595T
Other languages
English (en)
Inventor
Clarke Slemon
Bob Macel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Torcan Chemical Ltd
Original Assignee
Torcan Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torcan Chemical Ltd filed Critical Torcan Chemical Ltd
Application granted granted Critical
Publication of DE69428595D1 publication Critical patent/DE69428595D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69428595T 1993-11-04 1994-08-17 Herstellung von omeprazol und lansoprazol und dabei verwendete zwischenprodukte Expired - Lifetime DE69428595D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/145,572 US5374730A (en) 1993-11-04 1993-11-04 Preparation of omeprazole and lansoprazole
PCT/CA1994/000452 WO1995012590A1 (en) 1993-11-04 1994-08-17 Preparation of omeprazole and lansoprazole and intermediates useful therein

Publications (1)

Publication Number Publication Date
DE69428595D1 true DE69428595D1 (de) 2001-11-15

Family

ID=22513693

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69428595T Expired - Lifetime DE69428595D1 (de) 1993-11-04 1994-08-17 Herstellung von omeprazol und lansoprazol und dabei verwendete zwischenprodukte

Country Status (8)

Country Link
US (2) US5374730A (de)
EP (1) EP0724582B1 (de)
JP (1) JP2966097B2 (de)
AT (1) ATE206707T1 (de)
AU (1) AU7487594A (de)
CA (1) CA2170250C (de)
DE (1) DE69428595D1 (de)
WO (1) WO1995012590A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2236628T3 (es) * 1995-09-21 2005-07-16 Pharma Pass Ii Llc Composicion farmaceutica que contiene un omeprazol labil de acido, y procedimiento para su preparacion.
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
AU1538397A (en) * 1996-02-06 1997-08-28 Pdi-Research Laboratories, Inc. Synthesis of omeprazole-type pyridine derivatives and intermediates thereof
DE19643593A1 (de) * 1996-10-22 1998-04-23 Privatinstitut Fuer Informatik Vorrichtung und Verfahren zum frühzeitigen Erkennen und Verhindern unzulässiger Konzentrationsschwächen und des Einschlafens beim Autofahren und bei anderen Tätigkeiten, die hohe Konzentration erfordern
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
CA2204580A1 (en) * 1997-05-06 1998-11-06 Michel Zoghbi Synthesis of pharmaceutically useful pyridine derivatives
US6437139B1 (en) 1997-05-06 2002-08-20 Pdi-Research Laboratories, Inc. Synthesis of pharmaceutically useful pyridine derivatives
CA2295817C (en) 1997-07-11 2008-02-12 Eisai Co., Ltd. Method for producing pyridine compound
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6231795B1 (en) 1998-12-04 2001-05-15 The Dow Chemical Company Soft and flexible foams made from blends of alkenyl aromatic polymers and alpha-olefin/vinyl or vinylidene aromatic and/or sterically hindered aliphatic or cycloaliphatic vinyl or vinylidene interpolymers
US6852739B1 (en) * 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
US6362202B1 (en) 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6353005B1 (en) 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
KR100362947B1 (ko) * 1999-09-21 2002-11-30 주식회사 대웅 설폭시드 화합물의 제조방법
KR100359256B1 (ko) * 1999-10-06 2002-11-04 한미약품공업 주식회사 란소프라졸의 개선된 제조방법
EP1469839A2 (de) * 2002-01-25 2004-10-27 Santarus, Inc. Transmukosale verabreichung von protonenpumpeninhibitoren
KR100464174B1 (ko) * 2002-03-06 2005-01-03 코오롱유화주식회사 설피닐 벤즈이미다졸 유도체의 제조방법
US7211590B2 (en) * 2002-08-01 2007-05-01 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
EP1607088B1 (de) * 2003-03-17 2019-02-27 Takeda Pharmaceutical Company Limited Zusammensetzung mit kontrollierter freisetzung
EP1608649A2 (de) * 2003-03-28 2005-12-28 Sidem Pharma SA Verfahren zur herstellung von enantioselektiven sulfoxid-derivaten
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
ES2201936B1 (es) * 2003-11-10 2005-05-01 Union Quimico-Farmaceutica S.A. Procedimiento para la sintesis de pantoprazol e intermedios.
WO2005077936A1 (en) 2004-02-11 2005-08-25 Ulkar Kimya Sanayii Ve Ticaret A.S. Pyridine benzimidazole sulfoxides with high purity
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
TW200619198A (en) * 2004-12-10 2006-06-16 Ind Tech Res Inst Method for preparing 2-(2-pyridylmethylsulphinyl)benzimidazoles
WO2009122435A2 (en) * 2008-03-31 2009-10-08 Council Of Scientific & Industrial Research A simultaneous method for the preparation of a mixture of 3- acetoxy-17-acetamido-16-formyl-androst-5,17-diene and 3- acetoxy-2'-chloro-5-androsteno[17,16-b]pyridine
WO2010134099A1 (en) 2009-05-21 2010-11-25 Cadila Healthcare Limited One pot process for preparing omeprazole and related compounds
WO2013108068A1 (en) 2012-01-21 2013-07-25 Jubilant Life Sciences Limited Process for the preparation of 2-pyridinylmethylsulfinyl benzimidazoles, their analogs and optically active enantiomers
BR112022005578A2 (pt) 2019-09-24 2022-09-20 Prolacta Bioscience Inc Composições e métodos para tratamento de doenças inflamatórias e imunes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
JPS6150978A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
DK171989B1 (da) * 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler

Also Published As

Publication number Publication date
US5374730A (en) 1994-12-20
CA2170250C (en) 1997-09-16
EP0724582A1 (de) 1996-08-07
ATE206707T1 (de) 2001-10-15
EP0724582B1 (de) 2001-10-10
CA2170250A1 (en) 1995-05-11
JPH09504530A (ja) 1997-05-06
JP2966097B2 (ja) 1999-10-25
WO1995012590A1 (en) 1995-05-11
US5470983A (en) 1995-11-28
AU7487594A (en) 1995-05-23

Similar Documents

Publication Publication Date Title
DE69428595D1 (de) Herstellung von omeprazol und lansoprazol und dabei verwendete zwischenprodukte
DE69435221D1 (de) Magnesiumsalz des (-)-Enantiomers von Omeprazol und dessen Verwendung
ATE186535T1 (de) Verfahren zur herstellung von omeprazol
ES2173982T3 (es) Hidrato de acido 8 - alcoxiquinoloncarboxilico con una estabilidad excelente y procedimiento para producir el mismo.
DE69109519T2 (de) Verfahren zur Herstellung von Titandixoid.
DE69214537D1 (de) Zersetzung von organischen Hydroperoxiden
DE69231815D1 (de) Verfahren zur Herstellung von Cephalosporinen und Zwischenprodukte in diesem Verfahren
DE69221841D1 (de) Verfahren zur Herstellung von gereinigtem Xanthangummi
YU12000A (sh) Supstituisani 1,2,3,4,5,6-heksahidro-2,6-metano-3-benzazocin -10-oli, postupak za njihovo pripremanje i njihova primena kao lekova
NO982867L (no) Nye substituerte 4-(1H-benzimidazol-2-yl)£1,4|diazepaner som er anvendbare for behandling av allergiske sykdommer
DE69010963T2 (de) Herstellung von Adipinsäure aus Laktonen.
DE69228648T2 (de) Verfahren zur Herstellung von komplementären, bipolaren Transistoren
NO20011290L (no) Fremgangsmåte for fremstilling av et naftyridinkarboksylsyrederivat (metansulfonat-sesquihydrat)
MXPA02002355A (es) Procedimiento para la produccion de derivados de acido naftiridin-3-carboxilico.
DE69011367D1 (de) Verfahren zur Herstellung von substituierten 2,3-Pyridindicarbonsäuren durch aufeinanderfolgende Oxidation von substituierten Chinolinen.
DE3880953D1 (de) Chinolinderivate, verfahren zur herstellung davon und diese enthaltendes antibakterielles mittel.
DE69615276T2 (de) Verbessertes Verfahren zur Herstellung von 5-(Alkoxymethyl)-pyridin-2,3-dicarboxylat Salz
DE69109121T2 (de) Verfahren zur herstellung von substituierten pyridinen via 1-aza-1,3-butadiene und ihre zwischenprodukte.
DE69604327T2 (de) Herstellung von polyalkylierten Cyclopentadienen aus Isobornylcarboxylaten
DE69100200D1 (de) Verfahren zur industriellen herstellung von 3-sulfamoyl-4-chlor-n-(2,3-dihydro-2-methyl-1h-indol-1-yl)-benzamide ausgehend von 2,3-dihydro-2-methyl-1h-indol und hydroxylamine-o-sulfonsaeure.
ATE232533T1 (de) Carbapenemderivate und herstellungsverfahren dafür
ATE165347T1 (de) Verfahren zur herstellung pyridin-2,3- dicarboxylicsäure
DE68916172D1 (de) Verfahren zur kristallisierung und reinigung zur herstellung von stabilen kristallen von tetrakis 3-(3,5-di-tertiary-butyl-4-hydroxyphenyl)propionyloxymethyl-methan auf industrieller basis.
TR199600916A2 (tr) Sübstitüe edilmis benzol dikarbonik asit diguanidid'leri, bunlarin üretilmesine mahsus usul, bunlarin ilac veya diagnostik olarak kullanilmalari ve bunlari iceren ilac.
ATE250581T1 (de) Verfahren zur herstellung von 3-cyanopyridin aus 2-methyl-1,5-pentandiamin

Legal Events

Date Code Title Description
8332 No legal effect for de